Oculis to Present at Upcoming Investor Conferences
ZUG, Switzerland — Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company committed to enhancing eye care and preserving sight, has announced its participation in several important investor conferences. These events aim to provide insights into their innovative pipeline and foster engagement with investors.
Wells Fargo Healthcare Conference 2024
Oculis Management will attend the Wells Fargo Healthcare Conference from September 4-6, 2024. This prominent event is recognized for its emphasis on the healthcare sector and features a range of presentations from leading companies.
H.C. Wainwright 26th Annual Global Investment Conference
Additionally, Oculis is scheduled to present at the H.C. Wainwright 26th Annual Global Investment Conference. The company’s CEO, Riad Sherif, MD, will speak on September 11 at 9:30 am ET. This conference serves as a valuable platform for companies to connect with institutional investors and discuss their latest advancements.
Baird Global Healthcare Conference 2024
Following the H.C. Wainwright event, Oculis will participate in the Baird Global Healthcare Conference on September 10-11, 2024. CFO Sylvia Cheung will take part in a fireside chat on September 10 at 9:05 am ET, providing insights into the company's financial strategies and growth prospects.
One-on-One Meetings for Investors
During these conferences, Oculis will be available for one-on-one meetings with interested investors. It is advisable for investors to contact their representatives at the sponsoring institutions to arrange these meetings. Additionally, a link to access the company presentation will be shared on the Oculis website once it is finalized.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; Iceland: OCS.IC) focused on improving eye care and preserving sight. Their unique pipeline includes innovative product candidates such as OCS-01, which is designed for diabetic macular edema (DME) and managing inflammation and pain after cataract surgery. Another significant candidate, OCS-02 (licaminlimab), targets dry eye disease (DED) and non-infectious anterior uveitis.
Innovative Product Pipeline
As part of their commitment to developing groundbreaking treatments, the company is also advancing OCS-05, a neuroprotective candidate aimed at treating acute optic neuritis (AON). Oculis strives to enhance patient health and quality of life globally, leveraging its established presence in Switzerland, the U.S., and Iceland.
Contact Information
For further inquiries, please reach out to:
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577
Frequently Asked Questions
What is Oculis Holding AG focused on?
Oculis is dedicated to developing innovative biopharmaceutical solutions aimed at improving eye care and preserving sight.
When will Oculis present at the conferences?
Oculis will present at three key conferences in September, with specific dates for each event outlined in the article.
Who will represent Oculis at the conferences?
The company's CEO, Riad Sherif, and CFO, Sylvia Cheung, will be the main representatives presenting at the respective conferences.
How can investors schedule a meeting with Oculis?
Investors interested in one-on-one meetings should contact their representatives at the sponsoring institutions during the conferences.
Where can I find more information about Oculis?
For additional information, visit the official Oculis website, where updates and presentations will be posted.